
# Building Aseptic Resilience in Region without an Aseptic Hub

**Danny Forrest** 

Chief Pharmacist, Liverpool Heart and Chest Hospital NHS FT



## The Journey So Far.....



## NW Aseptic and Radiopharmacy Strategy Group

- Purpose- to address current and future demand and capacity issues for aseptically prepared products across the North West.
- Membership- Chiefs & Aseptic leads from the 3 ICSs, SPS QA, Radiopharmacy, HEE, Regional procurement.
- In the context of national recommendations, transformation of NHS aseptic services and NHS radiopharmacy services are essential to build capacity, capability and efficiencies within the system.

- Strong NW collaboration is required across the 3 integrated care systems (ICSs) with particular focus on 4 key areas (4Ps!);
- People (workforce recruitment/retention and training)
- Products (current and future demand for sterile products)
- Place (current and future aseptic estates)
- Partnerships (ICSs and commercial)
- The group will provide strategic transformational oversight to, and collaborate closely with, 3 other NW aseptic groups;
- NW Aseptic Services Group
- NW Outsourced Aseptic Services Oversight Group
- NW Radiopharmacy Services Group

# Challenges to Progress- Barriers, Pressures and Moving Parts

- Evolution of ICBs
- Money access/availability
- Time
- Trusts own internal pressures
- NHSE- Hub & spoke. Access to funding. Future intentions.
- NHSE- ISMP workstreams




## The 4Ps!


- Strong NW collaboration is required across the 3 integrated care systems (ICSs) with particular focus on 4 key areas (4Ps!);
- Place (current and future aseptic estates)
- People (workforce recruitment/retention and training)
- Products (current and future demand for sterile products)
- Partnerships (ICSs and commercial)


- 1. Lancashire and South Cumbria
- 2. Greater Manchester
- Cheshire and Merseyside


# Current situation in the NW....




## Place (Estate)









## **Places**

## Aseptic Facility Overview



21 aseptic facilities (operational)



10 Cheshire and Mersey



Population 2.7m



7 Greater Manchester



Population 2.8m



4 Lancashire and South Cumbria



Population 1.8m

24/09/2025 10

### Clean Air Device Overview



#### 111 Clean Air Devices



61 Cheshire and Mersey



Population 2.7m



36 Greater Manchester



Population 2.8m



14 Lancashire and South Cumbria



Population 1.8m

24/09/2025

## People

- Significant variation
- 20% vacancy (90 WTE)
- R&R issues;


Specialty area


Lack of career pathway

Little Succession planning for seniors

Candidate pool shrinking

Lack of capacity and capability for training focus





## **Products**

#### **Product Volume**

## 3-month period



226,000 doses



90,000 Outsourced



104,000 MS Licence



31,500 Section 10

## 12-month period (Projected figures)



904,000 doses



360,000 Outsourced



416,000 MS Licence



126,000 Section 10

24/09/2025

## Product type (excluding PN)



194 molecules



2602 presentations



14 molecules greater than 50 presentations



5-FU – 165 presentations (50 doses, 36 volumes, 2 diluent, 10 containers)



Carboplatin – 62 presentations, 21 ISMB band, 41 variations

24/09/2025 15

## Partnerships

As part of the work on place, people and products, stronger collaboration between Trusts across the NW will be required. The NW already has well established pharmacy groups (NW Directors of Pharmacy, NW aseptic service managers, NW aseptic strategy group) within which to shape technical services transformation. Stronger partnerships need to be developed with commercial suppliers to truly optimise NW demand and capacity to meet the needs of patients. Furthermore, wide stakeholder engagement and support is needed across NW ICBs, clinical teams, finance and logistics to realise a NW solution to the problem.


## 2 big NW aseptic surveys completed

- Challenge- aseptic apathy?
- What next?
- to address current and future demand and capacity issues for aseptically prepared products across the North West by building capacity, capability and efficiencies within the system.
- Reframed Hub and Spoke concept

The way to get started is to quit talking and begin doing.

Walt Disney

## The Journey So Far.....





#### Covered:

- Underpinning key reports
- Why need sterile products and who for
- Growing demand/lack of capacity/capability threat
- 4Ps survey data
- This is a healthcare risk, not a pharmacy service risk. Failure to invest will lead to an inability to treat.



Health and social care > Medicines, medical devices > Pharmacy > Transforming NHS pharmacy aseptic services in England



Department of Health & Social Care

#### Guidance

## Transforming NHS pharmacy aseptic services in England

Published 29 October 2020

**Applies to England** 

Contents

A national report for the Department of Health and Social Care by Lord Carter of Coles.



**NHS Medicines Manufacturing Review (NMMR21)** 

March 2022 (Commercial/confidential data removed)

NHS England and NHS Improvement

## People Considerations

#### **Considerations**

- Develop NW workforce strategy for aseptic staff, including recruitment & retention, training, career development and succession planning.
- Creating centralised teams to ensure consistent, high-quality training across the NW.
- Implementing standard procedures and processes for training
- Create a NW training repository. Document and video record training processes to prevent knowledge loss. Standardise and centralise training materials for easy access.
- Utilizing technology such as VR for innovative training methods
- Standardised JDs
- Seeking centralised funding and investment to support trainers, develop training programmes and infrastructure.
- Building relationships with universities and colleges. Collaborate with pharmacy schools and other educational bodies to integrate technical services training in relevant courses.
- Ensuring staff are given adequate time and resources to undertake



## Regional Training Co-ordinators

Key improvements;

#### Standardisation –

NW training document ratification process (design and approval of training materials) Digital platforms (learning hub, ET network) Training gap analysis

#### Collaboration-

NW Tech Service training group **Development-** Tech Services Educator Training vourse



#### Mission Statement

>FutureNHS

NHS **England** 


"Standardisation of training pathways, training resources and career development opportunities in technical services (aseptic)"





North West

Caroline Reid, Sonia Shaw, Jessica Taylor



#### **Technical Services Train the Trainer Course**

SHARE INFORMATION - COLLABORATE - SUPPORT - NETWORK - PROBLEM

training, possible trouble shooting options for difficult situations, and help to build trainer networks for future support. The course will also provide training tools and aids to support staff, and will be launched in 2025

#### Collaboration

The project has successfully improved the North West representation across the country, collaborating with the ISI working groups, London Regional Facilitator, Midlands Technical Services Working Group and NHS England NE&Y

discussions about the project and benefits brought for the NW

1. Price L., Jackson M., Risby G., Welsh S. Northern Pharmacy Technical Services Workforce Project Report. Specialist Pharmacy Service [internet]. 2021. Available from: https://www.sps.nhs.uk/articles/nort 2. Reid, C. Clinical Fellowship Project 2023. NHS England North West. Unpublished

Figure 2. Regional Standardisation of Guidance

**Documents Process Flow** 

Caroline reid@ithtr.nhs.uk; Sonia shaw@thtr.nhs.uk; Jessica taylor3@liverpoolft.nhs.uk

## Place Considerations

#### **Considerations**

- No spoke unit must be allowed to fail. Any decision to decommission a unit must be a strategic one informed by an assessment of demand and capacity across all 3 ICSs.
- Compile details on each unit's specific estate risks and repair costs. Risk stratify to prioritise
   NW case of need informed by an assessment of demand and capacity across all 3 ICSs.
   Develop standard business case template for local section 10 units (spoke)
- Compile details on each unit's specific equipment risks and replacement costs. Risk stratify
  to prioritise NW case of need informed by an assessment of demand and capacity across all 3
  ICSs.
- As part of NW product demand/supply and unit capacity analysis, optimisation of units
  output (including utilisation of MS licenses, attaining new MS licenses, maintaining existing
  MS licenses, extended operating hours, review of products made/sold to other Trusts) and
  costs/resources therein.
- As part of NW product demand/supply and unit capacity analysis, review need for the 3
   hibernating facilities to become operational and costs/resources therein.
- Within all this resilience work, ensure capacity inbuilt to absorb likely future activity rises.



## **Product Considerations**

#### **Considerations**

- How do we standardise variation in dose/volume/ container to increase efficiencies?
  - Uptake of licensed neonatal product
  - Standard specifications
  - Aseptic formulary
  - Medusa (primary injectables information source used by nursing staff on wards)
  - o Influence prescribers.
- Assessment of system drug costs due to change in sourcing

#### **Current work**

- •Review of top 10 products per category (CIVAs, MABs, Chemotherapy)
- •Identify products suitable for standardisation and production at scale
- Identify unwarranted variation



## Where should products be prepared?

#### Large scale manufacturing – batch units

- Planned work (make for stock)
- High volume of products made to standard specifications
- Products have long shelf life
- MS Specials (batch production)
- Products cheaper to produce economies of scale



#### Local facilities (spokes)

- Responsive
- Patient specific doses
- Products have short shelf life
- MS Specials or Section 10
- Products more expensive to produce



#### Criteria for batch units

- MS Licence
- Facility (or area of facility) designated to prepare high volume standard specification products
- Ability to distribute products around region
- Doesn't need a new bespoke facility
- Resilience from several hubs

#### Criteria for local facilities (spokes)

- Ability to prepare patient specific doses with quick turnaround times (within 24hours if needed)
- Ability to prepare clinical trials
- Some units to have ability to prepare ATMPs

#### Where do we need batch units?

- Location anywhere in NW region
- No limit to the number



#### Where do we need local facilities (spokes)?

• All hospitals receiving patient specific aseptic products require access to a spoke unit



#### **Criteria for batch unit products**

- Expiry ≥ 28 days
- Agreed standard specification
- Demand is at least 5,000 doses per annum



#### Criteria for local unit products


- Expiry ≤ 28 days
- Variable doses and presentation
- Demand is less than 5,000 doses per annum



## Partnerships Considerations

#### **Considerations**

- Further progress on analysis of product and place data will inform level of collaboration required between Trusts and between Trusts and commercial suppliers.
- Rationalise and standardise products to maximise productivity of MS units and release capacity in local units
- HEE representation on Pharmacy groups to advise on necessary collaboration with HEIs
- Engagement with clinical teams to be managed through pharmacy groups
- Engagement with ICBs, and specifically to support finance, needs to be defined. SROs required.



## Next Steps

- ICBs and relevant senior regional stakeholders to be appraised of the contents of this paper.
- Resources and investment needed for both capital and revenue in order to manage identified risks.
- Single Regional Pharmacy Aseptic Strategy
- PM support
- NW pharmacy groups to continue to work up details on demand, capacity and capability to optimise NW aseptic services
- NW pharmacy groups to work up assessment and risk stratification of aseptic units capital and revenue investment requirements.
- Develop NW workforce strategy for aseptic staff, including recruitment & retention, training, career development and succession planning

## **Challenges**

- Units immediate risks and requirements
- Co-ordination & Collaboration within and Across 3 ICSs
- Money/Business Cases
- Time and capacity to progress programme at pace

## Developing a resilient aseptic supply model without a hub

.....Questions?.....and also any Answers you might have!

